Svati H. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Svati H. Shah has a total of 752 co-authors. Here are the top co-authors by number of shared publications:
- William E. Kraus
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA
18 shared publications - Lydia Coulter Kwee
Duke Molecular Physiology Institute, Duke University School of Medicine
14 shared publications Carol Haynes
Duke Molecular Physiology Institute, Durham, North Carolina
13 shared publicationsChristopher B. Newgard
Duke Molecular Physiology Institute, Durham, North Carolina, USA
13 shared publicationsLydia Coulter Kwee
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA
12 shared publications- Pamela S. Douglas
Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina
12 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
α‐Hydroxybutyrate and Cardiovascular Outcomes in People Living With Type 2 Diabetes: An EXSCEL Post Hoc Analysis
- 27 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open Accessα‐Hydroxybutyrate and Cardiovascular Outcomes in People Living With Type 2 Diabetes: An EXSCEL Post Hoc Analysis
- Open Access
- 22 July 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (8) , 101640
Proteomic Signatures of High-Risk Coronary Plaque Features and Incident Events
- 22 July 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (8) , 101640
Open AccessProteomic Signatures of High-Risk Coronary Plaque Features and Incident Events
- 4 June 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 167, 108369
Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study
- 4 June 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 167, 108369
Design and Rationale of the pERSonalized cardIovascuLar dIsease prEvention, treatmeNt, and CarE (RESILIENCE) study
- Open Access
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy
BACKGROUND: Obesity and weight loss in adults have been associated with distinct metabolome and gut microbiome features, but the extent to which those associations apply to adolescent stages remain unclear. METHODS: The Pediatric Obesity Microbiome and Metabolism Study (POMMS) enrolled 220 adolescents aged 10–18 with severe obesity (OB) and 67 individuals who were healthy weight controls (HWCs). Blood, stool, and clinical measures were collected at baseline and after a 6-month obesity intervention for the OB group. Metabolomic profiling in serum using targeted quantitative mass spectrometry and microbiome profiling in stool were performed, and those features were assessed for associations with BMI, insulin resistance, and inflammation. Fecal microbiome transplants (FMT) were performed on germ-free mice using samples from both groups to assess effects on weight gain and metabolic pathways. RESULTS: Adolescents with OB exhibited higher serum branched-chain amino acid (BCAA) but lower branched-chain ketoacid (BCKA) levels compared with HWC. This pattern was sex- and age-dependent and differed from adults with obesity who show elevated levels of both BCAA and BCKA. Longitudinal analysis identified metabolic and microbial features correlated with changes in health measures during the intervention. The fecal microbiomes of adolescents with OB and HWC had similar diversity but differed in membership and functional potential. FMT from both OB and HWC donors had similar effects on mouse body weight, but specific taxa were linked to weight gain in recipients of FMT. CONCLUSION: Adolescents with OB have unique metabolomic adaptations and microbiome signatures compared with their HWC counterparts and adults with OB. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03139877 (Observational Study) and NCT02959034 (Repository). FUNDING SUPPORT: American Heart Association Grants: 17SFRN33670990, 20PRE35180195; National Institute of Diabetes and Digestive and Kidney Diseases Grant: R24-DK110492.
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Open AccessBranched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy
BACKGROUND: Obesity and weight loss in adults have been associated with distinct metabolome and gut microbiome features, but the extent to which those associations apply to adolescent stages remain unclear. METHODS: The Pediatric Obesity Microbiome and Metabolism Study (POMMS) enrolled 220 adolescents aged 10–18 with severe obesity (OB) and 67 individuals who were healthy weight controls (HWCs). Blood, stool, and clinical measures were collected at baseline and after a 6-month obesity intervention for the OB group. Metabolomic profiling in serum using targeted quantitative mass spectrometry and microbiome profiling in stool were performed, and those features were assessed for associations with BMI, insulin resistance, and inflammation. Fecal microbiome transplants (FMT) were performed on germ-free mice using samples from both groups to assess effects on weight gain and metabolic pathways. RESULTS: Adolescents with OB exhibited higher serum branched-chain amino acid (BCAA) but lower branched-chain ketoacid (BCKA) levels compared with HWC. This pattern was sex- and age-dependent and differed from adults with obesity who show elevated levels of both BCAA and BCKA. Longitudinal analysis identified metabolic and microbial features correlated with changes in health measures during the intervention. The fecal microbiomes of adolescents with OB and HWC had similar diversity but differed in membership and functional potential. FMT from both OB and HWC donors had similar effects on mouse body weight, but specific taxa were linked to weight gain in recipients of FMT. CONCLUSION: Adolescents with OB have unique metabolomic adaptations and microbiome signatures compared with their HWC counterparts and adults with OB. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03139877 (Observational Study) and NCT02959034 (Repository). FUNDING SUPPORT: American Heart Association Grants: 17SFRN33670990, 20PRE35180195; National Institute of Diabetes and Digestive and Kidney Diseases Grant: R24-DK110492.
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e045753
Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health Study
Background: The American Heart Association Predicting Risk of Cardiovascular Disease Events risk scores estimate cardiovascular disease (CVD) risk, including heart failure (HF) and atherosclerotic CVD (ASCVD) events. Whether they associate with subclinical CVD in an asymptomatic community population is unknown. Methods: We analyzed 1138 participants from the multicenter PBHS (Project Baseline Health Study) cohort, who underwent echocardiography and coronary artery calcium scoring and were free of known CVD. Subclinical CVD was defined as the presence of subclinical HF or subclinical coronary artery disease. Subclinical HF included left ventricular diastolic dysfunction, left ventricular hypertrophy, or low ejection fraction (0. Predicting Risk of CVD Events 10‐year risk score associations with subclinical CVD were assessed using logistic regression and area under the receiver operating characteristic curve analysis. Results: Median age was 52 (41–64) years; 64% were White; and 57% were women. Subclinical HF was found in 182 (16%) participants, predominantly with left ventricular diastolic dysfunction (14%). Diastolic dysfunction prevalence increased from 5.8% in low‐risk HF groups to 44.1% in intermediate‐/high‐risk HF groups. Each unit increase in 10‐year HF risk corresponded to 2.67‐fold higher odds of diastolic dysfunction (95% CI, 2.25–3.18; area under the curve, 0.81). Subclinical coronary artery disease was present in 466 (41%) participants, with prevalence increasing from 28.5% in low‐risk ASCVD groups to 79.3% in intermediate‐/high‐risk ASCVD groups. Each unit increase in 10‐year ASCVD risk was associated with 2.91‐fold higher odds of any coronary calcification (95% CI, 2.54–3.35; area under the curve, 0.80), increasing to 4.76‐fold for coronary artery calcium >100 (95% CI, 3.70–6.12; area under the curve, 0.86) and 5.60‐fold for coronary artery calcium >300 (95% CI, 3.89–8.05; area under the curve, 0.87). Conclusions: In an asymptomatic CVD‐free community sample, subclinical CVD was increasingly associated with higher 10‐year HF and ASCVD risks calculated by the Predicting Risk of CVD Events equations.
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e045753
Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health Study
Background: The American Heart Association Predicting Risk of Cardiovascular Disease Events risk scores estimate cardiovascular disease (CVD) risk, including heart failure (HF) and atherosclerotic CVD (ASCVD) events. Whether they associate with subclinical CVD in an asymptomatic community population is unknown. Methods: We analyzed 1138 participants from the multicenter PBHS (Project Baseline Health Study) cohort, who underwent echocardiography and coronary artery calcium scoring and were free of known CVD. Subclinical CVD was defined as the presence of subclinical HF or subclinical coronary artery disease. Subclinical HF included left ventricular diastolic dysfunction, left ventricular hypertrophy, or low ejection fraction (0. Predicting Risk of CVD Events 10‐year risk score associations with subclinical CVD were assessed using logistic regression and area under the receiver operating characteristic curve analysis. Results: Median age was 52 (41–64) years; 64% were White; and 57% were women. Subclinical HF was found in 182 (16%) participants, predominantly with left ventricular diastolic dysfunction (14%). Diastolic dysfunction prevalence increased from 5.8% in low‐risk HF groups to 44.1% in intermediate‐/high‐risk HF groups. Each unit increase in 10‐year HF risk corresponded to 2.67‐fold higher odds of diastolic dysfunction (95% CI, 2.25–3.18; area under the curve, 0.81). Subclinical coronary artery disease was present in 466 (41%) participants, with prevalence increasing from 28.5% in low‐risk ASCVD groups to 79.3% in intermediate‐/high‐risk ASCVD groups. Each unit increase in 10‐year ASCVD risk was associated with 2.91‐fold higher odds of any coronary calcification (95% CI, 2.54–3.35; area under the curve, 0.80), increasing to 4.76‐fold for coronary artery calcium >100 (95% CI, 3.70–6.12; area under the curve, 0.86) and 5.60‐fold for coronary artery calcium >300 (95% CI, 3.89–8.05; area under the curve, 0.87). Conclusions: In an asymptomatic CVD‐free community sample, subclinical CVD was increasingly associated with higher 10‐year HF and ASCVD risks calculated by the Predicting Risk of CVD Events equations.
- Open Access
Immune Aging is an Independent Risk Factor for Cardiovascular Disease
Cardiovascular disease remains the leading cause of mortality worldwide, yet substantial risk persists beyond traditional clinical and metabolic predictors. The immune system is a key mediator of this residual risk, but clinically scalable metrics of immune state are lacking. Here, we established the clinical and prognostic relevance of IMM-AGE, a system-level metric of immune aging derived from immune cell correlation structure. We developeda transcriptomic gene-ratio signature and optimized reduced-marker flow cytometry panels that accurately preserve IMM-AGE across blood fractions, platforms and cohorts. Applying these clinic-ready implementations across population-based and disease-specific datasets, we show that elevated IMM-AGE is consistently associated with cardiovascular phenotypes and disease. We leverage the UK biobank to show that incorporation of IMM-AGE into the PREVENT 10-year risk equation increase accuracy of risk stratification. We also show that in elderly patients undergoing transcatheter aortic valve replacement, baseline IMM-AGE independently predicted early maladaptive cardiac remodeling and one-year mortality. Finally, in the Baseline Health Study, a large longitudinal cohort, IMM-AGE stratified cardiovascular event risk among individuals with otherwise similar clinical profiles. Together, these findings establish immune aging as a transferable, biologically grounded risk dimension and support IMM-AGE as a practical tool for precision cardiovascular risk assessment.
Open AccessImmune Aging is an Independent Risk Factor for Cardiovascular Disease
Cardiovascular disease remains the leading cause of mortality worldwide, yet substantial risk persists beyond traditional clinical and metabolic predictors. The immune system is a key mediator of this residual risk, but clinically scalable metrics of immune state are lacking. Here, we established the clinical and prognostic relevance of IMM-AGE, a system-level metric of immune aging derived from immune cell correlation structure. We developeda transcriptomic gene-ratio signature and optimized reduced-marker flow cytometry panels that accurately preserve IMM-AGE across blood fractions, platforms and cohorts. Applying these clinic-ready implementations across population-based and disease-specific datasets, we show that elevated IMM-AGE is consistently associated with cardiovascular phenotypes and disease. We leverage the UK biobank to show that incorporation of IMM-AGE into the PREVENT 10-year risk equation increase accuracy of risk stratification. We also show that in elderly patients undergoing transcatheter aortic valve replacement, baseline IMM-AGE independently predicted early maladaptive cardiac remodeling and one-year mortality. Finally, in the Baseline Health Study, a large longitudinal cohort, IMM-AGE stratified cardiovascular event risk among individuals with otherwise similar clinical profiles. Together, these findings establish immune aging as a transferable, biologically grounded risk dimension and support IMM-AGE as a practical tool for precision cardiovascular risk assessment.
- Open Access
- 29 April 2026
- Published by Springer Nature in Metabolomics
- Vol. 22 (3) , 62
Metabolic markers of kidney function and oxidative stress are associated with heart failure with preserved ejection fraction (HFpEF) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)
Background and aim Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with heart failure with preserved ejection fraction (HFpEF), independent of shared risk factors. The aim of this study was to discover metabolic pathways associated with HFpEF in individuals with MASLD to explore shared mechanisms and identify biomarkers of risk. Methods We examined HFpEF cases and non-HF controls in the Duke CATHeterization GENetics (CATHGEN) study. HFpEF was defined as left ventricular ejection fraction (LVEF) ≥ 45%, diastolic dysfunction grade ≥ 1 on transthoracic echocardiogram (TTE), and history of clinical heart failure. MASLD was phenotyped using ICD codes or hepatic steatosis index (HSI) > 36, in the presence of ≥ 1 metabolic risk factor. Metabolomic profiling was performed in fasting plasma using targeted tandem flow injection (absolute quantification, n = 60) and non-targeted (relative quantification, n = 210) mass spectrometry. Logistic regression models tested the association between metabolite factors and HFpEF. An interaction term analyzed the influence of MASLD on associations between metabolites and HFpEF. Results A total of 430 participants were included; 247 (57.4%) had HFpEF. In participants with MASLD (N = 222, 51.6%), a factor composed of markers of kidney function, acylcarnitines, and modified amino acids was associated with HFpEF (OR: 2.2, 95% CI: 1.5–3.2, FDR-adjusted p-value = 0.002). The association of a PC composed primarily of ketoglutarate and phenyl sulfate with HFpEF was modified by MASLD (unadjusted p-value = 0.03). Conclusions Markers of kidney function and mitochondrial metabolism were associated with HFpEF in participants with MASLD. Mitochondrial energy pathways may link MASLD to HFpEF.
- 29 April 2026
- Published by Springer Nature in Metabolomics
- Vol. 22 (3) , 62
Open AccessMetabolic markers of kidney function and oxidative stress are associated with heart failure with preserved ejection fraction (HFpEF) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)
Background and aim Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with heart failure with preserved ejection fraction (HFpEF), independent of shared risk factors. The aim of this study was to discover metabolic pathways associated with HFpEF in individuals with MASLD to explore shared mechanisms and identify biomarkers of risk. Methods We examined HFpEF cases and non-HF controls in the Duke CATHeterization GENetics (CATHGEN) study. HFpEF was defined as left ventricular ejection fraction (LVEF) ≥ 45%, diastolic dysfunction grade ≥ 1 on transthoracic echocardiogram (TTE), and history of clinical heart failure. MASLD was phenotyped using ICD codes or hepatic steatosis index (HSI) > 36, in the presence of ≥ 1 metabolic risk factor. Metabolomic profiling was performed in fasting plasma using targeted tandem flow injection (absolute quantification, n = 60) and non-targeted (relative quantification, n = 210) mass spectrometry. Logistic regression models tested the association between metabolite factors and HFpEF. An interaction term analyzed the influence of MASLD on associations between metabolites and HFpEF. Results A total of 430 participants were included; 247 (57.4%) had HFpEF. In participants with MASLD (N = 222, 51.6%), a factor composed of markers of kidney function, acylcarnitines, and modified amino acids was associated with HFpEF (OR: 2.2, 95% CI: 1.5–3.2, FDR-adjusted p-value = 0.002). The association of a PC composed primarily of ketoglutarate and phenyl sulfate with HFpEF was modified by MASLD (unadjusted p-value = 0.03). Conclusions Markers of kidney function and mitochondrial metabolism were associated with HFpEF in participants with MASLD. Mitochondrial energy pathways may link MASLD to HFpEF.
- Open Access
Diastolic Age: A Cardiac Biological Clock Derived from Echocardiography and the PREVENT Heart Failure Risk Score
Background: Among cardiac measures, diastolic parameters demonstrate the earliest and most consistent age-related changes. This can be leveraged to develop a continuous left ventricular (LV) Diastolic Age from routine echocardiographic parameters. Analogous to how epigenetic clocks weight molecular markers against mortality risk, we calibrated Diastolic Age by weighting echocardiographic features against the validated PREVENT–Heart Failure (HF) risk score. Methods: We analyzed 1,952 participants from the Project Baseline Health Study (median age 50 [36–64] years, 54% female). The measure was derived using partial least-squares regression anchored on PREVENT-HF and calibrated within a healthy reference subgroup. External validation was performed in the WASE (n=1,708) and Stanford Cardiovascular Aging (n=313) cohorts. Associations with ASE-defined LV diastolic dysfunction (LVDD), epigenetic clocks, and major adverse cardiovascular events (MACE) were examined. Results: Diastolic Age correlated strongly with chronological age (r=0.78) with robust external validation (WASE r=0.76; Stanford r=0.82; calibration slopes ≈1.0). It increased progressively across grades of diastolic dysfunction and discriminated LVDD with an AUC of 0.89 (95% CI 0.87–0.92), and was independently associated with hypertension, diabetes, and elevated C-reactive protein. While correlated with the Levine (r=0.76) and Horvath (r=0.41) epigenetic clocks, residual analyses indicated that Diastolic Age captures a distinct cardiac-specific dimension of biological aging. Over median follow-up of 4.2 years, it independently predicted MACE (HR 2.30, 95% CI 1.70–3.18), with accelerated diastolic aging across all age groups among those with events. Discrimination was comparable to ASE-defined LVDD (C-index 0.83 vs. 0.82). Conclusions: Diastolic Age provides a continuous, echocardiography-derived measure of cardiac biological aging that complements categorical diastolic grading and epigenetic aging clocks, and independently predicts cardiovascular outcomes.
Open AccessDiastolic Age: A Cardiac Biological Clock Derived from Echocardiography and the PREVENT Heart Failure Risk Score
Background: Among cardiac measures, diastolic parameters demonstrate the earliest and most consistent age-related changes. This can be leveraged to develop a continuous left ventricular (LV) Diastolic Age from routine echocardiographic parameters. Analogous to how epigenetic clocks weight molecular markers against mortality risk, we calibrated Diastolic Age by weighting echocardiographic features against the validated PREVENT–Heart Failure (HF) risk score. Methods: We analyzed 1,952 participants from the Project Baseline Health Study (median age 50 [36–64] years, 54% female). The measure was derived using partial least-squares regression anchored on PREVENT-HF and calibrated within a healthy reference subgroup. External validation was performed in the WASE (n=1,708) and Stanford Cardiovascular Aging (n=313) cohorts. Associations with ASE-defined LV diastolic dysfunction (LVDD), epigenetic clocks, and major adverse cardiovascular events (MACE) were examined. Results: Diastolic Age correlated strongly with chronological age (r=0.78) with robust external validation (WASE r=0.76; Stanford r=0.82; calibration slopes ≈1.0). It increased progressively across grades of diastolic dysfunction and discriminated LVDD with an AUC of 0.89 (95% CI 0.87–0.92), and was independently associated with hypertension, diabetes, and elevated C-reactive protein. While correlated with the Levine (r=0.76) and Horvath (r=0.41) epigenetic clocks, residual analyses indicated that Diastolic Age captures a distinct cardiac-specific dimension of biological aging. Over median follow-up of 4.2 years, it independently predicted MACE (HR 2.30, 95% CI 1.70–3.18), with accelerated diastolic aging across all age groups among those with events. Discrimination was comparable to ASE-defined LVDD (C-index 0.83 vs. 0.82). Conclusions: Diastolic Age provides a continuous, echocardiography-derived measure of cardiac biological aging that complements categorical diastolic grading and epigenetic aging clocks, and independently predicts cardiovascular outcomes.
- Open Access
- 15 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Expanding clones, expanding aneurysms through macrophage-to-osteoclast differentiation
Abdominal aortic aneurysms (AAAs) are an age-related cause of sudden cardiac death and cardiovascular disease (CVD) morbidity with limited nonsurgical treatment options. In this issue of the JCI , Yonekawa et al. addressed the pathobiologic mechanisms of clonal hematopoiesis (CH), the age-related acquisition of expanded somatic clones in blood cells, as a potential driver of AAA. CH prevalence was high in patients being treated for AAA, and faster AAA expansion occurred over a period of one year in CH carriers. In an angiotensin II–induced model of AAA, mice carrying ten-eleven translocation 2 ( Tet2 ) mutations ( Tet2 -CH) displayed accelerated AAA development and macrophage reprograming to an osteoclast-like state. Inhibition of this differentiation, targeting RANK/RANKL with FDA-approved therapies like alendronate and denosumab, suppressed aneurysmal growth. These findings suggest that macrophage-to-osteoclast differentiation may underlie the risk and progression of AAA associated with age-related CH, a mechanism that is modifiable through existing therapeutics.
- 15 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Open AccessExpanding clones, expanding aneurysms through macrophage-to-osteoclast differentiation
Abdominal aortic aneurysms (AAAs) are an age-related cause of sudden cardiac death and cardiovascular disease (CVD) morbidity with limited nonsurgical treatment options. In this issue of the JCI , Yonekawa et al. addressed the pathobiologic mechanisms of clonal hematopoiesis (CH), the age-related acquisition of expanded somatic clones in blood cells, as a potential driver of AAA. CH prevalence was high in patients being treated for AAA, and faster AAA expansion occurred over a period of one year in CH carriers. In an angiotensin II–induced model of AAA, mice carrying ten-eleven translocation 2 ( Tet2 ) mutations ( Tet2 -CH) displayed accelerated AAA development and macrophage reprograming to an osteoclast-like state. Inhibition of this differentiation, targeting RANK/RANKL with FDA-approved therapies like alendronate and denosumab, suppressed aneurysmal growth. These findings suggest that macrophage-to-osteoclast differentiation may underlie the risk and progression of AAA associated with age-related CH, a mechanism that is modifiable through existing therapeutics.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (3) , e019011
Risk in Women Emerges at Lower Coronary Plaque Burden Than in Men: PROMISE Trial
BACKGROUND: Quantitative coronary plaque measures differ in prognostic value between women and men. It remains unclear whether cardiovascular risk increases proportionally with plaque extent in both sexes. We aimed to compare cardiovascular risk trajectories across quantitative coronary plaque measures in women and men with stable chest pain. METHODS: We analyzed data from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) coronary computed tomography angiography arm, quantifying total coronary plaque volume and burden (plaque burden [PB]; % vessel volume), including calcified, noncalcified, and low-attenuation components. Associations with major adverse cardiovascular events (death, myocardial infarction, or unstable angina hospitalization) were assessed using sex-stratified spline Cox models over a median 26 months (interquartile range, 18–34). RESULTS: Among 4267 patients (mean age, 60.4±8.2; 2199 women), plaque was less frequent in women (55% versus 75%; P <0.001), with lower total plaque volume but similar total PB and incident major adverse cardiovascular events (2.3% versus 3.4%). Major adverse cardiovascular event risk became elevated at lower PB in women than in men: for total PB, hazard ratio crossed 1.0 at 20% in women versus 28% in men, reaching hazard ratio 1.5 at 32% in women versus 42% in men, respectively. Noncalcified PB showed a similar pattern, crossing hazard ratio 1.0 at 7% in women versus 9% in men; hazard ratio 1.5 at 13% in women versus 20% in men. Findings were similar after adjustment for atherosclerotic cardiovascular disease risk score. CONCLUSIONS: In women, major adverse cardiovascular events appeared to emerge at a lower PB, and to rise more sharply. Findings support sex-specific interpretation of coronary computed tomography angiography-derived plaque metrics for timely intervention in women. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01174550.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (3) , e019011
Risk in Women Emerges at Lower Coronary Plaque Burden Than in Men: PROMISE Trial
BACKGROUND: Quantitative coronary plaque measures differ in prognostic value between women and men. It remains unclear whether cardiovascular risk increases proportionally with plaque extent in both sexes. We aimed to compare cardiovascular risk trajectories across quantitative coronary plaque measures in women and men with stable chest pain. METHODS: We analyzed data from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) coronary computed tomography angiography arm, quantifying total coronary plaque volume and burden (plaque burden [PB]; % vessel volume), including calcified, noncalcified, and low-attenuation components. Associations with major adverse cardiovascular events (death, myocardial infarction, or unstable angina hospitalization) were assessed using sex-stratified spline Cox models over a median 26 months (interquartile range, 18–34). RESULTS: Among 4267 patients (mean age, 60.4±8.2; 2199 women), plaque was less frequent in women (55% versus 75%; P <0.001), with lower total plaque volume but similar total PB and incident major adverse cardiovascular events (2.3% versus 3.4%). Major adverse cardiovascular event risk became elevated at lower PB in women than in men: for total PB, hazard ratio crossed 1.0 at 20% in women versus 28% in men, reaching hazard ratio 1.5 at 32% in women versus 42% in men, respectively. Noncalcified PB showed a similar pattern, crossing hazard ratio 1.0 at 7% in women versus 9% in men; hazard ratio 1.5 at 13% in women versus 20% in men. Findings were similar after adjustment for atherosclerotic cardiovascular disease risk score. CONCLUSIONS: In women, major adverse cardiovascular events appeared to emerge at a lower PB, and to rise more sharply. Findings support sex-specific interpretation of coronary computed tomography angiography-derived plaque metrics for timely intervention in women. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01174550.